🎉 #Gate Alpha 3rd Points Carnival & ES Launchpool# Joint Promotion Task is Now Live!
Total Prize Pool: 1,250 $ES
This campaign aims to promote the Eclipse ($ES) Launchpool and Alpha Phase 11: $ES Special Event.
📄 For details, please refer to:
Launchpool Announcement: https://www.gate.com/zh/announcements/article/46134
Alpha Phase 11 Announcement: https://www.gate.com/zh/announcements/article/46137
🧩 [Task Details]
Create content around the Launchpool and Alpha Phase 11 campaign and include a screenshot of your participation.
📸 [How to Participate]
1️⃣ Post with the hashtag #Gate Alpha 3rd
Lyon: Remains optimistic about the development of Stone Pharmaceutical Group, maintaining a "highly confident outperform the market" rating.
Jin10 data reported on May 30 that Lyon published a research report indicating that although the sales of Enbipusi from Shanghai Pharmaceuticals (01093.HK) faced challenges, the first quarter performance still met expectations, with a year-on-year net profit fall of 8.4%. It is believed that Shanghai Pharmaceuticals' profits have bottomed out in the first quarter. In addition to the market's focus on SYS6010, the management also revealed that there are two other products that will achieve potential licensing cooperation, each exceeding $5 billion in scale. Lyon expressed continued optimism about Shanghai Pharmaceuticals' development, believing that its early R&D pipeline is competitive globally and has a differentiated innovative drug platform, maintaining a "highly confident outperform the market" rating for Shanghai Pharmaceuticals, with a target price of HKD 13.8.